Acute myeloid leukemia (AML) is curable for some patients, but the odds depend heavily on age, genetic features of the leukemia, and how well it responds to initial treatment. The overall five-year survival rate is about 33%, based on national data from 2015 to 2021, and that number has been climbing steadily. For younger adults with favorable genetics, cure rates can exceed 50%. For older adults, long-term survival remains much harder to achieve, though newer drug combinations are improving outcomes even for patients who can’t tolerate aggressive chemotherapy.
What “Cured” Means in AML
Doctors don’t typically use the word “cure” at diagnosis. Instead, the first milestone is complete remission, which means the bone marrow shows fewer than 5% abnormal cells and blood counts have recovered to near-normal levels. Reaching remission is necessary but not sufficient. Most relapses happen within the first three years after remission, and after that point the risk drops sharply. Relapse after five years of sustained remission is uncommon, occurring in fewer than 3% of patients. Once someone passes the three-year mark in first remission, they are generally considered potentially cured.
Overall Survival by the Numbers
The national five-year relative survival rate for AML has risen from about 30% in 2013 to roughly 37% in the most recent estimates. Death rates have been falling by an average of 0.8% per year over the past decade, reflecting gradual improvements in treatment. These are averages across all ages and disease subtypes. Individual odds can be significantly better or worse depending on a few key factors.
Why Age Matters So Much
AML is one of the cancers where age creates the starkest divide in outcomes. Younger adults, generally under 60, have five-year survival rates approaching 50%. Older adults face far tougher odds: population studies show five-year survival of only 3% to 8% for patients over 60. Part of this gap is biological. AML in older patients more often carries high-risk genetic changes. But fitness matters too. Intensive chemotherapy, which offers the best chance at deep remission, is harder to tolerate with age. Median overall survival for treated patients aged 65 to 69 is about 10 months, dropping to around 6 months for those 75 to 79.
That said, newer lower-intensity drug combinations have changed the landscape for older and frailer patients. A regimen combining venetoclax with azacitidine produces complete remission in about 66% of patients who aren’t candidates for intensive chemotherapy, compared to 28% with older low-intensity treatment alone. Median survival with this combination is roughly 15 months, and long-term follow-up at over three years shows durable remissions in a meaningful subset of patients. This isn’t a cure for most, but it represents a significant shift from what was available even five years ago.
Children Have the Best Outcomes
Pediatric AML has seen dramatic improvements over recent decades, with overall survival rates now around 70%. Children generally tolerate intensive chemotherapy better and are more likely to have favorable disease biology. Even among children who relapse, about 35% to 42% survive five years after the relapse, and that number climbs to roughly 52% for those who receive a stem cell transplant after relapsing.
Genetic Risk Groups Shape Your Prognosis
Modern AML treatment begins with genetic testing of the leukemia cells, because the specific mutations driving the cancer are among the strongest predictors of whether it can be cured. The European LeukemiaNet classification sorts patients into three risk categories based on these mutations.
- Favorable risk: Estimated five-year survival around 53%. These patients often achieve long-term remission with chemotherapy alone.
- Intermediate risk: Median survival of about 17 months. A stem cell transplant in first remission is frequently recommended.
- Adverse risk: Median survival under 10 months. Even with aggressive treatment, long-term cure is difficult.
Two of the most commonly tested mutations illustrate how genetics influence the disease. A mutation in the NPM1 gene is associated with a good prognosis. Patients with this mutation alone (without certain unfavorable co-mutations) have five-year survival rates above 70%. In contrast, a mutation called FLT3-ITD carries a poor prognosis even after intensive treatment. Patients who have FLT3-ITD without the protective NPM1 mutation have a median survival of only about 18.5 months and a five-year survival near 23%. When both mutations are present together, the outlook falls in between: roughly 56% five-year survival. This is why the specific genetic profile of your leukemia matters as much as, or more than, the diagnosis itself.
Stem Cell Transplant as a Path to Cure
For patients with intermediate or high-risk AML, a stem cell transplant from a donor (allogeneic transplant) offers the strongest chance at long-term disease control. The transplant works through two mechanisms: high-dose chemotherapy before the transplant destroys remaining leukemia cells, and the donor’s immune cells then patrol for and attack any surviving cancer, a process called the graft-versus-leukemia effect.
Five-year overall survival after transplant in first remission is roughly 52% to 56% in published studies. Relapse rates after transplant range from about 25% for standard-risk patients to 60% for the highest-risk subtypes. Transplant isn’t offered to everyone. It carries significant risks including graft-versus-host disease, infections, and organ damage, so it’s typically reserved for patients whose leukemia genetics suggest chemotherapy alone won’t be enough. For patients with favorable-risk disease who achieve deep remission, consolidation chemotherapy without transplant is often the preferred approach.
Measuring How Deep the Remission Goes
One of the most important advances in AML treatment is the ability to measure minimal residual disease, or MRD. This refers to tiny amounts of leukemia that are invisible under a standard microscope but detectable with sensitive molecular or flow-based tests. Reaching MRD-negative status, meaning no detectable residual leukemia, substantially improves the odds of staying in remission.
Among patients in complete remission, those who test MRD-negative have an estimated five-year survival of 67%, compared to 31% for those who remain MRD-positive. Achieving MRD negativity is associated with a threefold reduction in the risk of death. Still, the picture is nuanced. About 30% of MRD-negative patients in remission eventually relapse, likely because current tests can’t detect every last leukemia cell. And a small fraction of MRD-positive patients, around 16%, remain disease-free at five years. MRD results are increasingly used to guide decisions about whether to proceed with a transplant or adjust treatment intensity.
The Relapse Window
For patients who achieve remission, the first two to three years are the period of highest risk. Most relapses occur during this window. If you remain in continuous remission for three years, the probability of the leukemia returning drops dramatically, to less than 10% of the earlier relapse rate. By five years, late relapse becomes rare. This is why oncologists often frame the three-year mark as a turning point and the five-year mark as a reasonable definition of cure, even though lifelong monitoring through periodic blood tests remains standard practice.
The trajectory after relapse is considerably harder. Second remissions are possible, and some patients are cured after a transplant following relapse, but overall survival after relapse is substantially lower than after first treatment. This is why getting the deepest possible remission during initial therapy is so critical.